Article
HER2 mutation as an emerging target in advanced breast cancer.
Cancer science - 1 Jul 2024
Bon Giulia, Di Lisa Francesca Sofia, Filomeno Lorena, Arcuri Teresa, Krasniqi Eriseld, Pizzuti Laura, Barba Maddalena, Messina Beatrice, Schiavoni Giulia, Sanguineti Giuseppe, Botti Claudio, Cappelli Sonia, Pelle Fabio, Cavicchi Flavia, Puccica Ilaria, Costantini Maurizio, Perracchio Letizia, Maugeri-Saccà Marcello, Ciliberto Gennaro, Vici Patrizia
Abstract excerpt
HER2 activating mutations have emerged as oncogenic drivers and therapeutic targets in a variety of human tumors. In breast cancer, these deregulations occur at low frequency, and are mostly detected in HER2-nonamplified, metastatic disease. Preclinical evidence has clarified the role of hotspot mutations in HER2 constitutive activation, defining them as an alternative mechanism to HER2 gene amplification....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.